Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Capecitabine, Carboplatin, and Bevacizumab for Metastatic or Unresectable Gastroesophageal Junction and Gastric Adenocarcinoma

NCT00780494 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT00780494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00780494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Capecitabine, Carboplatin, and Bevacizumab for Metastatic or Unresectable Gastroesophageal Junction and Gastric Adenocarcinoma
Lead sponsor
Stanford University
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2009
Completion date
December 31, 2017
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric (stomach) cancer, gastrointestinal stromal tumor (gist), neoplasm of cardioesophageal junction, stomach cancer